Tracing the Cellular Origin of Retinoblastoma: Insights from RB1-Deficient Retinal Organoids

Study Background and Research Question

Retinoblastoma (Rb) is the most common primary intraocular cancer in children, arising during retinal development. The malignancy is almost universally associated with biallelic inactivation of the RB1 tumor suppressor gene, which encodes the retinoblastoma protein (pRB)—a critical regulator of cell cycle progression at the G1/S checkpoint via E2F transcription factors. Although loss of RB1 is a well-established driver for Rb, a long-standing question in ocular oncology has been: which specific retinal cell type first gives rise to tumorigenesis following RB1 loss? Past evidence, mostly derived from late-stage tumor samples or indirect models, has suggested multiple possible origins, including retinal progenitor cells (RPCs), photoreceptors, and interneurons. However, species differences and the lack of dynamic, human-based models have limited definitive conclusions. The reference study (Cell Death and Disease, 2026) addresses this knowledge gap using next-generation retinal organoid systems.

Key Innovation from the Reference Study

The principal innovation of this research lies in its use of human-induced pluripotent stem cell (hiPSC)-derived retinal organoids (ROs) with precise RB1 knockout to longitudinally trace cell state transitions during tumorigenesis. By applying single-cell RNA sequencing and orthotopic xenograft models, the study directly observes the earliest events in Rb initiation at single-cell resolution. Most notably, the research identifies ATOH7+/RXRγ+ nascent cone precursors (CPs) as the earliest and most definitive cellular origin of human retinoblastoma—a finding that clarifies a major controversy in the field and highlights the stage-specific vulnerability of cone precursor cells to RB1 loss.

Methods and Experimental Design Insights

The authors generated RB1-deficient (RB1−/−) and heterozygous (RB1+/−) hiPSC lines, differentiating these into three-dimensional retinal organoids that recapitulate the sequential generation of all major retinal cell types. This system enables temporal dissection of lineage progression and the effects of RB1 deficiency. The following methodological innovations were central:

• Use of isogenic hiPSCs to ensure that observed phenotypes were attributable to RB1 status rather than genetic background.
• Longitudinal sampling of organoids at defined developmental stages, capturing dynamic transitions from neurogenic RPCs (nRPCs) to early-born retinal subtypes.
• Single-cell transcriptomics to identify and track molecular signatures unique to each retinal lineage and to detect abnormal proliferation or survival patterns.
• Functional validation via orthotopic xenograft transplantation, demonstrating that tumorigenic cells from RB1−/− organoids recapitulate human Rb in vivo.
• Multi-omics approaches to uncover candidate therapeutic targets, including validation by genetic knockdown and pharmacological inhibition.

Core Findings and Why They Matter

The study's major discoveries reshape our understanding of retinoblastoma initiation:

• RB1 Loss Drives nRPC Overproliferation: In RB1−/− retinal organoids, the earliest response to RB1 loss was a marked overproliferation of ATOH7+ neurogenic retinal progenitor cells. This disrupts normal retinal lamination and lineage specification.
• Nascent Cone Precursors as the True Cell-of-Origin: Single-cell RNA-seq revealed that, among the early-born lineages, only ATOH7+/RXRγ+ nascent cone precursors survived, expanded abnormally, and ultimately drove tumorigenesis. These cells exhibited hallmarks of early Rb, including uncontrolled proliferation and resistance to differentiation cues (reference study).
• Contrasts with Monoallelic Inactivation: In contrast, RB1+/− organoids with residual pRB expression showed overproliferation of nRPCs but did not progress to cone precursor-driven tumors, instead resembling benign retinocytoma.
• Therapeutic Target Validation: Integrative multi-omics highlighted potential intervention points, with knockdown experiments and small molecule inhibitors demonstrating that targeted disruption of specific pathways can suppress tumorigenic proliferation and induce apoptotic cell death.

These findings have significant implications: they pinpoint a narrow developmental window and a specific cell type most vulnerable to oncogenic transformation, providing a refined framework for early detection and targeted therapy development in Rb.

Comparison with Existing Internal Articles

Several recent articles complement these insights:

• The article "Nascent Cone Precursors as the Cellular Origin of Human Retinoblastoma" offers an accessible summary of how RB1-deficient retinal organoids were used to longitudinally trace the emergence of tumorigenic cell populations, aligning with the detailed mechanistic evidence from the reference study.
• While the current paper focuses on retinoblastoma, related internal articles such as "TAI-1: A Next-Generation Hec1 Inhibitor for Precision Cancer Research" and "TAI-1 Hec1 Inhibitor: Precision Workflows for Cancer Research" explore the use of highly potent Hec1 inhibitors to induce apoptotic cell death in diverse cancers, including models relevant to cell cycle dysregulation and chromosomal instability. Though these articles do not address Rb specifically, they reinforce the broader translational theme: that precise targeting of mitotic regulators (e.g., Hec1) can drive cancer cell proliferation inhibition and synergize with classical chemotherapeutics in difficult-to-treat cancers, such as triple negative breast and liver cancer.

Limitations and Transferability

While the use of hiPSC-derived retinal organoids overcomes many of the limitations inherent to animal models and late-stage clinical samples, some constraints remain. The in vitro organoid system, despite recapitulating key aspects of human retinogenesis, lacks the full complexity of the ocular microenvironment, including immune and vascular components. This may influence the observed response to RB1 loss and the efficacy of candidate therapies. Furthermore, while nascent cone precursors are shown to be the earliest origin of Rb in this model, tumor heterogeneity in clinical cases may result from additional mutational events or microenvironmental factors that were not recapitulated in vitro. Finally, the translation of findings from organoid models to in vivo human disease, and ultimately to clinical intervention, requires further validation.

Protocol Parameters

• hiPSC Differentiation: Initiate retinal organoid differentiation following established protocols for human stem cells; use isogenic controls for RB1+/+, RB1+/−, and RB1−/− lines.
• Longitudinal Sampling: Collect organoids at multiple developmental time points (e.g., weeks 4, 8, 12) to capture dynamic lineage transitions.
• Single-Cell RNA-Sequencing: Use droplet-based platforms to analyze gene expression at the single-cell level, focusing on markers such as ATOH7 and RXRγ for cone precursor identification.
• Xenograft Validation: Orthotopically transplant tumorigenic cells into immunodeficient mice to assess in vivo tumorigenicity and recapitulation of human Rb features.
• Target Validation: Employ siRNA knockdown or small molecule inhibitors to interrogate candidate oncogenic pathways identified via multi-omics.

Research Support Resources

For researchers seeking to model apoptotic cell death induction or cancer cell proliferation inhibition in systems characterized by mitotic dysregulation—such as those highlighted by the vulnerability of cone precursors in RB1-deficient contexts—validated small molecule tools are essential. TAI-1 (SKU B4892) is a highly potent, first-in-class Hec1 inhibitor that disrupts Hec1-Nek2 interactions, leading to chromosomal misalignment and apoptosis in cancer cells, as detailed in product information and related literature. Its robust in vitro and in vivo efficacy, including synergy with chemotherapeutics and specificity for cancer cells, makes it a valuable resource for translational studies in triple negative breast cancer research, liver cancer research, and mechanistic models of mitotic regulation. For protocol details and stability recommendations, consult the product page at APExBIO.